Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy

Fig. 2

Multiplex immunohistochemistry panels displaying immune compositional changes in tumor microenvironment (n = 24) . As explorative setting, some cases with available tissues in HPD, non-HPD PD and PR/CR group. HPD hyperprogressive disease, Non-HPD PD non-HPD progressive disease, PR/CR partial response/complete response, TIL tumor infiltrating lymphocytes, NK natural killer cells, DC dendritic cells

Back to article page